When not statistically better than MEKi alone, the combination of C5aR antagonists with MEK inhibition shows a trend toward increased tumor shrinkage, causes death of tumor cells, and causes long-term effects on the tumor microenvironment including modulation of macrophage phenotype and dendritic cell accumulation. The gene discussed is C5AR1; the disease is neoplasm.